Search

Displaying results 5891 - 5900 of 6198 in total
  1. Drug

    Hydrocortisone valerate

    go.drugbank.com/drugs/DB14544
    ApprovedVet approved

  2. Drug

    TA-NIC

    go.drugbank.com/drugs/DB05445
    Investigational

    TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients.

  3. Drug

    Amuvatinib

    go.drugbank.com/drugs/DB12742
    Investigational

    Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3.

  4. Drug

    Tolperisone

    go.drugbank.com/drugs/DB06264
    Investigational

    Tolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels.

  5. Drug

    Calcimycin

    go.drugbank.com/drugs/DB19408
    Investigational

    Calcimycin is an ionophore and polyether antibiotic derived from Streptomyces chartreusensis.

  6. Drug

    Ocadusertib

    go.drugbank.com/drugs/DB21732
    Investigational

    Ocadusertib is under investigation in clinical trial NCT05848258 (An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis).

  7. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal cancer). ...

  8. Drug

    Etilamfetamine

    go.drugbank.com/drugs/DB13285
    Experimental

    Like other amphetamines, this amphetamine analog was used as an appetite suppressant in the 1950s.

  9. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum.

  10. Drug

    Tuxobertinib

    go.drugbank.com/drugs/DB21508
    Investigational

    Tuxobertinib is under investigation in clinical trial NCT04209465 (A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.).